Vinpocetine

Cerebrovascular disease is one of the disease categories with the highest fatality rate worldwide. Improving cerebral metabolism and protecting nerve cells are the core directions of clinical treatment for such diseases. Vinpocetine is an indole alkaloid derivative. By inhibiting the activity of phosphodiesterase and increasing the content of cGMP, the messenger for vascular smooth muscle relaxation, it selectively dilates cerebral blood vessels and increases cerebral blood flow without affecting the systemic circulation. Meanwhile, it can also inhibit platelet aggregation, reduce blood viscosity and improve cerebral hypoxia. It is mainly used clinically to improve various cognitive and motor dysfunctions caused by sequelae of cerebral infarction, sequelae of cerebral hemorrhage, cerebral arteriosclerosis, etc. It is a commonly used drug for long-term management of cerebrovascular diseases in middle-aged and elderly people.

In recent years, with the acceleration of global population aging, the prevalence of cerebrovascular diseases has continued to rise, driving the steady growth of market demand for vinpocetine. At present, the global market size has exceeded 500 million US dollars, and the compound annual growth rate is maintained at about 4%. China is one of the major consumer markets for vinpocetine. The domestic preparation market size is close to 1.5 billion yuan. The overall competitive pattern is characterized by the coexistence of original research drugs and generic drugs. Oral dosage forms have been included in the scope of national centralized procurement, and the winning bid price has dropped by more than 60% compared with that of previous years, which further improves the accessibility of medication for patients and also drives the continuous increase in demand for upstream active pharmaceutical ingredients.

The original research enterprise of vinpocetine is Gedeon Richter Plc. of Hungary, and the original research trade name is "Kailikang". Its core compound patent expired worldwide in 2004. The main dosage forms approved for the original research product include tablets and injections. The common specification of tablets is 5mg, and the specification of injections is 2ml:10mg. The original research product has been included in the *Catalogue of Reference Preparations of Chemical Drugs* of China, and is also listed in the FDA Reference Preparations Catalogue. In terms of domestic API registration, at present, more than 15 enterprises have obtained approval for vinpocetine API through CDE registration (status A), and multiple domestic generic drugs corresponding to both oral and injection preparations have been approved for marketing. (Data as of June 2025, please refer to the official website of CDE for the latest information.)

CATO can provide a full set of vinpocetine impurity reference standards, which strictly comply with the compliance requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA. Most products are in regular stock. Orders placed before 16:00 can be shipped on the same day, which can fully meet the reference standard use needs of the whole process such as API R&D, quality research, production quality control, etc.